- Izotropic highlights recurrent challenges in current breast imaging technologies and the need for high-resolution, true 3D imaging
- The IzoView breast CT scan technology is created for accurate, compression-free imaging for women who have dense breast tissue
- Increased screening demands and regulatory momentum underscore the opportunities for dedicated breast CT solutions
- IZOZF’s innovative approaches highlight the company’s mission to improve diagnosis, detection, and care for people globally
Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device firm leading imaging-based solutions for better diagnosis, screening, and treatment of breast cancer patients, is bringing the challenges of current screening systems and the unique potential of the IzoView Breast CT Imaging solutions as part of efforts to mark Breast Cancer Awareness Month (ibn.fm/Hml57).
Breast cancer accounts for a third of cancer diagnoses among American women, making the need for better imaging solutions critical. Current solutions like tomosynthesis, mammography, and ultrasound are limited by tissue overlap, compression, and a high rate of false positives. These issues are quite common among women with dense breast tissue, a situation common among over 50% of women within the screening-age group.
The firm’s IzoView Breast CT was created to solve these issues. IzoView can capture about 500 high-resolution images in less than 10 seconds with the patients lying face down and without breast compression. Studies at UC Davis, where the initial breast CT technology was created and licensed exclusively to Izotropic, have revealed malignant masses to be more obvious on optimized breast CT than on DBT or mammography, with a spatial resolution reaching 100 times more than magnetic resonance imaging.
Izotropic’s strategy attempts to close the gap between MRI and digital breast tomosynthesis, giving imaging centers and hospitals a better, mid-range option that boosts the accuracy of detection, devoid of the attendant complexity and cost of MRI technology. IzoView’s projected price of USD $500,000 means it will be adopted across the healthcare ecosystem.
With regulatory organizations like the U.S. Preventive Services Task Force and the FDA scaling up efforts in ensuring better imaging for women with dense tissues, Izotropic’s solution perfectly syncs with policy directions and emerging clinical needs. Recent mandates in America necessitate breast density notifications after mammography, highlighting the urgency and market opportunity for better imaging options.
With a core focus on the breast imaging industry, Izotropic is changing the way diagnosis and the comfort of patients are provided. These updates highlight the firm’s vision to empower clinicians with next-gen imaging tools that help improve patient outcomes and diagnostic confidence and save human lives.
For more information, visit the company’s website at www.IzoCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at ibn.fm/IZOZF
